FinnCap Reiterates Corporate Rating for Synairgen (SNG)

Synairgen (LON:SNG)‘s stock had its “corporate” rating restated by stock analysts at FinnCap in a report released on Wednesday. They currently have a GBX 35 ($0.49) price objective on the stock. FinnCap’s price target would indicate a potential upside of 185.71% from the company’s previous close.

Shares of Synairgen (LON SNG) opened at GBX 12.25 ($0.17) on Wednesday. The company has a market capitalization of $14.71 and a P/E ratio of -408.33. Synairgen has a 52 week low of GBX 6.88 ($0.10) and a 52 week high of GBX 32 ($0.45).

COPYRIGHT VIOLATION WARNING: This article was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at

Synairgen Company Profile

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease.

Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with's FREE daily email newsletter.

Leave a Reply